Mosaic ImmunoEngineering Agrees to Acquire Clinical Necropto

- The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy combinations HUNTINGTON BEACH, CA / ACCESSWIRE / April 29, 2024 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the &...

Related Keywords

Steven King , Jay Carlson , Vuong Trieu , Exchange Commission , Oncotelic Therapeutics Inc , Mosaic Immunoengineering Inc , Mosaic Immunoengineering , Oncotelic Therapeutics , Necroptosis Cancer Therapies , Cancer Therapies , Vascular Disrupting Agents , Check Point Inhibitors , Necroptosis Cancer , Artificial Intelligence , Private Securities Litigation Reform Act ,